Friday, February 27, 2026

Xspray Pharma appoints Blake Leitch as CEO, Per Andersson to become CSO

Xspray Pharma has announced a leadership change at the top: the company’s Board of Directors has appointed Blake Leitch as Chief Executive Officer (CEO). The appointment is expected to take effect no later than June 1, 2026.

Current CEO Per Andersson will remain in the role until Leitch assumes the position, and will then transition to Chief Scientific Officer (CSO). The company said the move is intended to sharpen its commercial focus while accelerating development of its portfolio.

Experience and future roles

According to the company, Leitch brings more than 20 years of international marketing and sales experience in the pharmaceutical industry. He is currently Vice President and Head of Europe Commercial at Biocon Biologics and a member of its Executive Leadership Team. Previous roles include leadership positions at Biogen and Bayer.

As CSO, Andersson is expected to take primary responsibility for research and development activities, including further development of Xspray Pharma’s HyNap technology platform and expansion of the company’s pipeline.

Shift toward a commercial pharma company

In its announcement, Xspray Pharma pointed to its ongoing shift toward becoming a commercial pharmaceutical company. The company said two drug candidates are currently under regulatory review. Xspray’s development strategy is based on its patented HyNap platform, aimed at creating improved versions of established protein kinase inhibitors.

Xspray Pharma is listed on Nasdaq Stockholm.